Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 247

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 247
---
 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 
In accordance with the assumptions used as of December 31, 2024, undiscounted defined pension benefits expected to be paid are as follows:
  Summary of undiscounted defined pension benefits
 
                Amount      
----------------------------
             $              
      2025   825            
      2026   871            
      2027          1,055   
      2028          1,081   
      2029          1,203   
Thereafter         33,858   
     Total         38,893   
 
The weighted average duration of the defined benefit obligation is 14.0 years.
 
If variations in the following assumptions had occurred during 2024, the impact on the Company’s pension benefit obligation of $22,403 as of December 31, 2024, would have been as follows:
  Summary of impact on pension benefit obligation
 
                Assumption                     Increase            Decrease      
---------------------------------------------------------------------------------
                                             $                  $                
Change in discount rate of 0.25%                     (822   )   694              
Change in discount rate of 0.25%                     (822   )   694              
Change in salary rate of 0.25%               410                         (560   )
Change in pension rate assumption by 0.25%   72                           (97   )
Change mortality by one year                        1,009              (1,178   )

F-32
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

16.   Warrants
--------------
 
Warrant activity for the years ended December 31, 2024, 2023 and 2022, was as follows:
  Summary of warrants activity reclassified equity
 
                                                                                       Number           Weighted average exercise price          Amount       
--------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                   #                                                      $   $               
Balance at December 31, 2022                                                             -                                             -            -         
                                                                                         -                                             -            -         
Balance at December 31, 2023                                                             -                                             -